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Case Report 
Renal Granulomatosis Post Intravesical Bacillus Calmette-Guerin 
Therapy for Non-muscle-invasive Bladder Cancer 
Karen Tran-Harding, Rashmi T Nail; Halemane Ganesh 
Department of Diagnostic 
Radiology, University of 
Kentucky Chandler Medical 
Center, Lexington, KY, USA 
~ Intravesical Bacillus Calmette-Guerin (BCG) immunotherapy is a proven, 
~ effective treatment for intennediate- and high-risk non-muscle-invasive bladder 
~ cancer. Minor side effects are common and expected but systemic effects can 
~ occur in <5% of treated patients. We present a rare case of a 49-yea.r-old male 
that presented with fever and chills after 3 weeks of intravesical BCG therapy 
post transurethral resection of bladder tumor. New renal lesions were present on 
contrast-enhanced computed tomography scan which was histologically proven to 
be necrotizing renal granulomatosis. 
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INTRODUCI'ION 
ff or over 40 years intravesical BCG has been the gold 
J standard treatment for intennediate- and high-risk 
non-muscle-invasive bladder cancer (NMIBC) after 
transurethral bladder resection.Pl BCG is an attenuated 
live strain of Mycobacterium bm is, and although its 
mechanism of action is not completely understood, it is 
believed that the treatment works through an immune 
response and a direct tumor response. [21 
Adjuvant BCG is highly effective in reducing 
the risk of recurrence of high-grade NMIBC 
by up to 70% compared with transurethral 
resection.!31 For carcinoma in situ (CIS), BCG has 
been shown to generate a complete response in 
up to 70%--90% of cases_[4J Minor toxic reactions 
such as urinaiy frequency, urgency, dysuria, and 
hematuria have been reported in 27%- 90% of the 
patientsYJ Granulomatous complications are very 
uncommon and include entities such as prostatitis, 
epididymo-orchitis, cystitis, pyelonephritis, and 
abscessesYl The incidence of significant renal 
complications is significantly less and varies from 
0.2% to 2% with renal granulomatosis occmTing in 
0.1 % of treated patientsYl We report a rare case of 
renal granulomas seen on imaging post intravesical 
BCG therapy for NMIBC. 
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CASE REPORT 
Our patient is a 49-year-old male with a histmy of 
high-grade Tl urothelial cell carcinoma of the bladder who 
underwent induction Bacillus Calmette-Guerin (BCG) 
immunotherapy, and repeat biopsies of the bladder 
which were negative. Smveillance with a computed 
tomography (CT) urogram demonstrated a suspicious 
nodular focus along the tight lateral wall of the bladder. 
Subsequent two office cystoscopies demonstrated no 
evidence of tumor recurrence or abnonnalities. The 
patient, however, later underwent paitial cystectomy 
2 months later where the pathology was negative for 
malignancy. Repeat bladder biopsies 8 months after 
surgery revealed urothelial CIS. The patient elected 
to undergo a second induction course of BCG. After 
completing 4 of the 6 treatments, the patient developed 
low-grade fever/chills and low back pain and was 
seen in the emergency department. Contrast-enhanced 
CT (CECT) scan of the abdomen which was petfonned 
as part of the workup showed a roughly 2 cm mass-like 
Address for correspondence: Dr. Karen Tran-Harding, 
Department of Diagnostic Radiology, University of Kentucky 
Chandler Medical Center, 800 Rose Street, HX315E, 
Lexington, KY, USA. 
E-mail: karentran@uky.edu 
This is an open aa:ess journal, and articles are distributed under the terms of the Creative 
Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to 
remix, tweak, and build upon the work non--rommercially, as long as appropriate credit is 
given and the new creations are licensed under the identical terms. 
For reprints contact: reprints@rnedknow.rom 
How to cite this article: Tran-Harding K, Nair RT, Ganesh H. Renal 
Granulomatosis Post lntravesical Bacillus Calmette-Guerin Therapy 
for Non-muscle-invasive Bladder Cancer. J Clin Imaging Sci 2018;8:18. 
Available FREE in open access from: http://\vww.dinicalimagingscience. 
org/text. asp 72018/8/1/18/230280 
© 2018 Journal of Clinical Imaging Science I Published by Wolters Kluwer - Medlcnow 
[Downloaded free from http://www.clinicalimagingscience.org on Thursday, December 6, 2018, IP: 128.163.8.74) 
Tran-Harding. et aL: Renal granulomatosis post BCG therapy for NMIBC 
area in the lower pole of the right kidney with moderate 
perinephric inflammatory changes [Figme la and b]. 
Smaller subcentin1eter ill-defined hypodense foci were 
also seen. A primaiy renal mass was suspected, and a 
repeat CECT scan pe1fo1med 3 weeks later demonstrated 
a persistent mas -like hypodense lesion in the light kidney 
with significantly improved perinephric inflammat01y 
changes [Figure 2a and b]. The differential included 
infection or inflammation. PrimaIY renal malignancies 
such as renal cell carcinoma and mothelial cell carcinoma 
and infiltrative masses such as lymphoma continued to 
be the main suspicions, and a CT-guided biopsy was 
recommended for histological confimrntion [Figure 3a]. 
Histopathology confirmed marked chronic inflammation 
and necrotizing granulomas without evidence for 
Figure 1: A 49-year-old male with a history ofhigh-grade Tl urothelial cell 
carcinoma of the bladder undergoing induction bacillus Calmette--Guerin 
immunotherapy. Initial presentation with fevers and chills after 3 weeks 
(4 of 6 treatments) of intravesical bacillus Calmette--Guerin therapy. 
( a) Axial contrast-enhanced computed tomography scan of the abdomen 
through the level of the kidney showing mass-like low attenuation 
lesion (yellow star) in the interpolar region of the right kidney with 
moderate surrounding perinephric inflammatory changes (blue arrow). 
(b) Coronal reformat contrast-enhanced computed tomography scan 
of the abdomen and pelvis showing mass-like low attenuation lesion 
(yellow star) in the interpolar region of the right kidney with moderate 
surrounding perinephric inflammatory changes (blue arrow). There is 
also mild diffuse bladder wall thickening (red arrow). 
Figure 3: A 49-year-old male with a history of high-grade Tl 
urothelial cell carcinoma of the bladder undergoing induction bacillus 
Calmette--Ouerin immunotherapy. Initial presentation with fevers 
and chills after 3 weeks (4 of 6 treatments) of intravesical Bacillus 
Calmette-Guerin therapy. ( a)Axial computed tomography of the abdomen 
through the level of the kidneys demonstrates a percutaneous computed 
tomography-guided biopsy of the lesion (blue circle). (b) Core needle 
biopsy from right renal mass showing marked chronic inflammation 
with granulomas (red circles). Special stains for acid-fast bacilli (Fite) 
and fungi (GMS) were negative (not shown). 
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malignancy [Figure 3b]. The primaiy clinical team 
decided to manage the patient conservatively with close 
follow-up due to resolution of the symptoms. Altl10ugh 
antituberculous therapies are instituted in ome cases 
there continue to be a lack of consensus regaI·ding 
approp1iate management of renal granulomatosis. The 
patient then finished his fifth instillation of BCG. Eight 
months later, a CECT scan showed inte1val resolution 
of the right renal lesions with mild residual co1tical 
scarring [Figure 4a and b]. On repeat cystoscopy and 
biopsy 8 months later, the patient was noted to have 
recunent non-invasive high-grade papillfilY urothelial 
cell caI·cinoma. The patient has since had a radical 
cystectomy with ileal conduit urinaiy diversion. 
DISCUSSION 
Intravesical BCG has proven to be an effective treatment 
for intermediate- and high-risk NMIBC.£11 High-risk 
Figure 2: A 49-year-oldmale with a history ofhigh-grade Tl urothelial cell 
carcinoma of the bladder undergoing induction bacillus Calmette--Guerin 
immunotherapy. Initial presentation with fevers and chills after 3 weeks 
(4 of 6 treatments) of intravesical bacillus Calmette--Guerin therapy. 
(a) Axial contrast-enhanced computed tomography of the abdomen 
through the level of the kidneys shows low attenuation lesions 
(yellow star) in the interpolar region of the right kidney with improving 
perinephric inflammatory changes 3 weeks later (blue arrow). (b) Coronal 
reformat contrast-enhanced computed tomography scan through the 
abdomen showing low attenuation lesions (yellow star) in the interpolar 
region of the right kidney with improving perinephric inflammatory 
changes 3 weeks later (blue arrow). 
Figure 4: A 49-year-old male with a history ofhigh-grade Tl urothelial cell 
carcinoma of the bladder undergoing induction bacillus Calmette--Guerin 
immunotherapy. Initial presentation with fevers and chills after 
3 weeks (4 of 6 treatments) of intravesical bacillus Calmette--Guerin 
therapy. (a) Axial contrast-enhanced computed tomography scan of the 
abdomen through the level of the kidneys showing interval resolution 
of the right renal lesions with mild residual cortical scarring 8 months 
later (blue arrow). (b) Coronal reformat contrast-enhanced computed 
tomography scan showing interval resolution of the right renal lesions 
with mild residual cortical scarring 8 months later (blue arrow). 
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NMIBC is defined as any transitional cell carcinoma 
of the bladder with high-grade papillaiy stage Ta or Tl 
tumors and any patient with CIS.Pl BCG immunotherapy 
treatment is scheduled for patients that have had a 
complete transurethral resection of tumor and consists 
of once weekly inte1val treatment for a total of six 
treatments.Pl 
The definition of BCG failure includes high-grade 
tumor recurrence.Pl Patients considered to be the 
highest risk are more likely to fail BCG treatment and 
ai·e recommended an early cystectomy as in the case 
with our patient.r6J BCG is usually well tolerated with 
severe systemic complications only occun"ing in <5% of 
patients.r7J It is debatable whether the complications result 
from a form of hypersensitivity reaction or an active 
mycobacterial infection.Pl Minor reactions ai·e usually 
mild, transient, and easily managed. Flu-like symptoms 
occur in patients within the first 24-48 h following 
intravesical instillation and are usually explained by the 
inflammatory reaction niggered by the BCG.[7) IlTitative 
lower m"inaiy u·act symptoms and gross hematuria ai·e 
also common and usually occur after third instillation.[41 
A single-dose of quinolone 6 h after instillation might 
decrease side effects and improve tolerability for minor 
reactions .[7) Other rare systemic complications include 
granulomatous reactions, pneumonitis and/or hepatitis, 
aithralgia, epididymitis, sepsis, rash, ureteral obsuuction, 
conu·acted bladder, renal abscess, and cytopenia.[41 
Severe complications can be prevented by careful patient 
selection and safe adminisu·ation practices. Treatment 
of severe complications can require antituberculous 
medications for 3-o months.[7) 
The incidence of renal toxicity from BCG is 
anywhere from 0.2% to 2% with the development of 
a granulomatous renal mass occurring in <0.1 % of 
patients.r5.s1 In some rep01ts, renal disease presented as 
pyelonephtitis after the third or fourth instillation doses. 
It can also present as flank pain or urinaiy frequency.rs1 
Other patients such as in our case present with features of 
renal mass.rs1 It has been hypothesized that renal affliction 
by BCG therapy may be related to vesicoureteral reflux 
that commonly occurs after transuretht·al resection of 
bladder tmnor.r91 
Imaging of post intravesical therapy, BCG granulomas 
can present as enhancing lesions on CECT scans)5J Renal 
manifestations may include pyelonephtitis or abscesses 
with a segmental disu·ibution and pe1fuepht·ic su·anding)81 
Some may even mimic expansile masses or present as 
multiple hypodense lesions with the kidney)5J A "central 
unaffected calyx sign" has been described that shows 
BCG granulomatosis as a solid mass in the kidney 
with a normal calyx centrally.P01 The main differential 
considerations would, however, include primaiy renal 
neoplasms such as renal cell cai·cinoma or infilu·ative 
conditions such as lymphoma or leukemia Imaging 
can be quite inconclusive in the vast majotity of the 
cases of renal granulomatosis such as in our case 
especially given the extremely low incidence of the 
condition. It would be pmdent to obtain histological 
confi1mation by image-guided percutaneous biopsy 
if there is no convincing improvement on subsequent 
follow-up imaging. Once confirmed, renal granulomas 
may be u·eated with rifainpin and isoniazid for 
3- 6 months.rs1 Sometimes, no treatment is undertaken 
and these granulomas tend resolve spontaneously as m 
our case. rs1 
CONCLUSION 
BCG is the gold standai·d therapy for NMIBC. Although 
it is usually well tolerated, a small number of patients 
can have systemic side effects. As renal granulomas 
though can present in a vatiety of different ways, it is 
essential to have high clinical suspicion to consider 
post BCG treatment reaction as a possible differential 
diagnosis. This case demonstrates the pmdence of 
strict follow-up imaging so that prompt therapy can be 
initiated when necessaiy while the renal lesions are still 
asymptomatic. Although extremely rare, recognition of 
imaging findings of renal granulomas with an appropriate 
history is imp01tant to distinguish it from a primaiy renal 
or metastatic neoplastic process to avoid unnecessaiy 
surgical procedures and to prese1ve renal parenchyma. 
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